Brief: Aurobindo Pharma Says Co Receives USFDA Approval For Dapagliflozin Tablets, 5 Mg And 10 Mg
07/04/2026 13:48
April 7 (Reuters) - Aurobindo Pharma Ltd ARBN.NS: AUROBINDO PHARMA - AUROBINDO PHARMA RECEIVES USFDA APPROVAL FOR DAPAGLIFLOZIN TABLETS, 5 MG AND 10 MG AUROBINDO PHARMA - ELIGIBLE FOR 180 DAYS SHARED GENERIC DRUG EXCLUSIVITY FOR DAPAGLIFLOZIN TABLETS Source text: https://tinyurl.com/rdf89uy8 Further company coverage: ARBN.NS ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aurobindo Pharma
See all newsBrief: Aurobindo Pharma Gets Tax Order Confirming Total Disputed Amount 46 Million Rupees
India's Aurobindo Pharma falls after US FDA flags observation at Telangana facility
Brief: Aurobindo Pharma Says US FDA Inspected API Manufacturing Facility Of Unit Apitoria Pharma
Brief: Aurobindo Pharma Gets USFDA Final Approval For Beclomethasone Dipropionate HFA Inhalation Aerosol
Brief: Aurobindo Pharma Says US FDA Inspected Unit-IV Of Apitoria Pharma From September 7 To September 11